|
FR104E
(fr)
|
|
|
|
|
|
US5843708A
(en)
|
1988-01-05 |
1998-12-01 |
Ciba-Geigy Corporation |
Chimeric antibodies
|
|
ES2052027T5
(es)
|
1988-11-11 |
2005-04-16 |
Medical Research Council |
Clonacion de secuencias de dominio variable de inmunoglobulina.
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
WO1991016056A1
(fr)
|
1990-04-16 |
1991-10-31 |
The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce |
Emploi d'agonistes de recepteur purinergique utilises comme agents antineoplastiques
|
|
ES2136092T3
(es)
|
1991-09-23 |
1999-11-16 |
Medical Res Council |
Procedimientos para la produccion de anticuerpos humanizados.
|
|
US5397703A
(en)
|
1992-07-09 |
1995-03-14 |
Cetus Oncology Corporation |
Method for generation of antibodies to cell surface molecules
|
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
|
US5900407A
(en)
|
1997-02-06 |
1999-05-04 |
Inspire Pharmaceuticals, Inc. |
Method of treating dry eye disease with uridine triphosphates and related compounds
|
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
|
US6946129B1
(en)
|
1999-06-08 |
2005-09-20 |
Seattle Genetics, Inc. |
Recombinant anti-CD40 antibody and uses thereof
|
|
DE19939653A1
(de)
|
1999-08-13 |
2001-02-22 |
Thomas Huenig |
Verwendung CD28 spezifischer monoklonaler Antikörper zur Herstellung einer pharmazeutischen Zusammensetzung
|
|
JP4210454B2
(ja)
|
2001-03-27 |
2009-01-21 |
日本たばこ産業株式会社 |
炎症性腸疾患治療剤
|
|
JP3871503B2
(ja)
|
1999-08-30 |
2007-01-24 |
日本たばこ産業株式会社 |
免疫性疾患治療剤
|
|
ATE363290T1
(de)
|
1999-10-04 |
2007-06-15 |
Novartis Vaccines & Diagnostic |
Cd40 antagonist zur behandlung von psoriasis
|
|
WO2001045691A2
(fr)
|
1999-12-22 |
2001-06-28 |
Inspire Pharmaceuticals, Inc. |
Methode de traitement de maladies du tractus gastro-intestinal au moyen d'agonistes de recepteurs purinergiques
|
|
JP2003520828A
(ja)
|
2000-01-27 |
2003-07-08 |
ジェネティクス インスティテュート，エルエルシー |
Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
|
|
US20020031512A1
(en)
|
2000-04-19 |
2002-03-14 |
M. C. Pasch |
CD40 antagonists for use in treating psoriasis and other inflammatory skin conditions
|
|
US20030059427A1
(en)
|
2000-04-28 |
2003-03-27 |
Force Walker R. |
Isolation and characterization of highly active anti-CD40 antibody
|
|
JP3597140B2
(ja)
|
2000-05-18 |
2004-12-02 |
日本たばこ産業株式会社 |
副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
|
|
EP1326896B1
(fr)
|
2000-10-02 |
2010-11-24 |
Novartis Vaccines and Diagnostics, Inc. |
Anticorps humains diriges contre cd40
|
|
DE10050935A1
(de)
|
2000-10-11 |
2002-05-02 |
Tegenero Gmbh |
Verwendung CD28 spezifischer monoklonaler Antikörper zur Stimulation von Blutzellen, welche kein CD28 tragen
|
|
US8501471B2
(en)
|
2000-10-18 |
2013-08-06 |
Sloan-Kettering Institute For Cancer Research |
Uses of monoclonal antibody 8H9
|
|
WO2002032375A2
(fr)
|
2000-10-18 |
2002-04-25 |
Sloan-Kettering Institute For Cancer Research |
Utilisations d'anticorps monoclonal 8h9
|
|
US20020102264A1
(en)
|
2000-10-18 |
2002-08-01 |
Cheung Nai-Kong V. |
Uses of monoclonal antibody 8H9
|
|
US8414892B2
(en)
|
2000-10-18 |
2013-04-09 |
Sloan-Kettering Institute For Cancer Research |
Uses of monoclonal antibody 8H9
|
|
RU2261723C2
(ru)
|
2000-12-14 |
2005-10-10 |
Фудзисава Фармасьютикал Ко.,Лтд. |
Молчащие анти-cd28-антитела и их применение
|
|
EP1345969B1
(fr)
|
2000-12-26 |
2010-08-11 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Anticorps anti-cd28
|
|
AR036993A1
(es)
|
2001-04-02 |
2004-10-20 |
Wyeth Corp |
Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
|
|
CN101508734A
(zh)
|
2001-04-27 |
2009-08-19 |
协和发酵麒麟株式会社 |
抗cd40单克隆抗体
|
|
WO2003028712A2
(fr)
*
|
2001-09-28 |
2003-04-10 |
Universite Libre De Bruxelles |
Agonistes de recepteur purinergique et pyrimidinergique pour le traitement de maladies immunitaires mediees par le lymphocyte t cd4+ active
|
|
WO2003029296A1
(fr)
|
2001-10-02 |
2003-04-10 |
Chiron Corporation |
Anticorps humains diriges contre le cd40
|
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
|
PA8557501A1
(es)
|
2001-11-12 |
2003-06-30 |
Pfizer Prod Inc |
Benzamida, heteroarilamida y amidas inversas
|
|
WO2003045978A2
(fr)
|
2001-11-26 |
2003-06-05 |
Chiron Corporation |
Traitement aux anticorps monoclonaux anti-cd40 antagonistes utilise pour traiter la sclerose en plaques
|
|
US20080199471A1
(en)
|
2002-03-01 |
2008-08-21 |
Bernett Matthew J |
Optimized cd40 antibodies and methods of using the same
|
|
CA2478082C
(fr)
|
2002-03-08 |
2016-02-02 |
Sloan-Kettering Institute For Cancer Research |
Utilisations d'anticorps 8h9 monoclonaux
|
|
DE10212108A1
(de)
|
2002-03-13 |
2003-10-02 |
Tegenero Ag |
Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung
|
|
ES2295639T3
(es)
|
2002-06-13 |
2008-04-16 |
Crucell Holland B.V. |
Agonistas del receptor ox40=(=cd134) y uso terapeutico descripcion.
|
|
DE10230223A1
(de)
|
2002-07-04 |
2004-01-22 |
Tegenero Ag |
Mikropartikel mit CD28-spezifischen monoklonalen Antikörpern
|
|
US7052694B2
(en)
|
2002-07-16 |
2006-05-30 |
Mayo Foundation For Medical Education And Research |
Dendritic cell potentiation
|
|
PL375144A1
(en)
|
2002-07-30 |
2005-11-28 |
Bristol-Myers Squibb Company |
Humanized antibodies against human 4-1bb
|
|
US7291331B1
(en)
|
2002-09-11 |
2007-11-06 |
La Jolla Institute For Allergy And Immunology |
Methods of treating OX40 medicated recall immune responses
|
|
EP2410332A1
(fr)
|
2002-11-21 |
2012-01-25 |
The University Of Utah |
Méthode d'identification de modulateurs purinergiques du système olfactif
|
|
CN1753912B
(zh)
|
2002-12-23 |
2011-11-02 |
惠氏公司 |
抗pd-1抗体及其用途
|
|
US20070104688A1
(en)
|
2003-02-13 |
2007-05-10 |
City Of Hope |
Small interfering RNA mediated transcriptional gene silencing in mammalian cells
|
|
KR20060052681A
(ko)
|
2003-05-23 |
2006-05-19 |
와이어쓰 |
Ｇｉｔｒ 리간드, ｇｉｔｒ 리간드-연관 분자, 항체 및그의 용도
|
|
US20090191213A9
(en)
|
2003-07-02 |
2009-07-30 |
Novo Nordisk A/S |
Compositions and methods for regulating NK cell activity
|
|
GB0324498D0
(en)
|
2003-07-21 |
2003-11-26 |
Aventis Pharma Inc |
Heterocyclic compounds as P2X7 ion channel blockers
|
|
EP1600164A3
(fr)
|
2003-09-22 |
2006-05-17 |
TeGenero AG |
Utilisation d'une substance liant le CD28 dans la production d'une composition pharmaceutique à effet dose-dépendant
|
|
US7288638B2
(en)
|
2003-10-10 |
2007-10-30 |
Bristol-Myers Squibb Company |
Fully human antibodies against human 4-1BB
|
|
WO2005041892A2
(fr)
|
2003-11-03 |
2005-05-12 |
Cornell Research Foundation, Inc |
Inhibition du recepteur des purines en tant que strategie therapeutique au niveau de la moelle epiniere et du cerveau
|
|
CA2544364A1
(fr)
|
2003-11-04 |
2005-05-19 |
Chiron Corporation |
Utilisation d'anticorps anti-cd40 antagonistes pour le traitement de la leucemie lymphocytique chronique
|
|
EP1684869B1
(fr)
|
2003-11-04 |
2011-07-20 |
Novartis Vaccines and Diagnostics, Inc. |
Procedes de therapie pour des cancers lies a la cellule b
|
|
US8277810B2
(en)
|
2003-11-04 |
2012-10-02 |
Novartis Vaccines & Diagnostics, Inc. |
Antagonist anti-CD40 antibodies
|
|
EP2301575A1
(fr)
|
2003-11-04 |
2011-03-30 |
Novartis Vaccines and Diagnostics, Inc. |
Procédé de thérapie pour tumeurs solides exprimant l'antigène de la surface de cellule CD40
|
|
DK1684805T3
(da)
|
2003-11-04 |
2010-10-04 |
Novartis Vaccines & Diagnostic |
Anvendelse af antagonist anti-CD40-monoklonale antistoffer til behandling af multipel myeloma
|
|
EP1682178B8
(fr)
|
2003-11-04 |
2010-09-01 |
Novartis Vaccines and Diagnostics, Inc. |
Procedes de therapie pour des cancers exprimant l'antigene cd40
|
|
DE10352900A1
(de)
|
2003-11-11 |
2005-06-16 |
Tegenero Ag |
Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von B-CLL
|
|
US20050136055A1
(en)
|
2003-12-22 |
2005-06-23 |
Pfizer Inc |
CD40 antibody formulation and methods
|
|
DK1707627T3
(da)
|
2003-12-25 |
2012-12-17 |
Kyowa Hakko Kirin Co Ltd |
Antagonistisk anti-CD40-antistofmutant.
|
|
EP1747206A1
(fr)
|
2004-04-29 |
2007-01-31 |
Abbott Laboratories |
Analogues d'amino-tétrazoles et méthodes d'utilisation
|
|
US20050261239A1
(en)
*
|
2004-05-23 |
2005-11-24 |
Universiteit Van Maastricht |
Use of ATP for the manufacture of a medicament for treating certain inflammatory conditions, oxidative stress and fatigue
|
|
US20060099203A1
(en)
|
2004-11-05 |
2006-05-11 |
Pease Larry R |
B7-DC binding antibody
|
|
AU2005259221B2
(en)
|
2004-07-01 |
2011-02-10 |
Innate Pharma |
Antibodies binding to receptors KIR2DL1, -2, 3 but not KIR2DS4 and their therapeutic use
|
|
US20080057070A1
(en)
|
2004-11-04 |
2008-03-06 |
Chiron Corporation |
Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
|
|
DE102004063494A1
(de)
|
2004-12-23 |
2006-07-13 |
Tegenero Ag |
Antikörper
|
|
ES2732623T3
(es)
|
2005-01-06 |
2019-11-25 |
Innate Pharma Sa |
Tratamientos y métodos de combinación anti-KIR
|
|
ES2374603T3
(es)
|
2005-01-06 |
2012-02-20 |
Novo Nordisk A/S |
Agentes de unión a kir y procedimientos de uso de los mismos.
|
|
US8551483B2
(en)
|
2005-01-06 |
2013-10-08 |
Innate Pharma S.A.S. |
Methods of treating viral infections by administering KIR2DL-binding antibodies
|
|
EP3058955B1
(fr)
|
2005-03-24 |
2019-05-29 |
Millennium Pharmaceuticals, Inc. |
Anticorps se liant à l'ov064 et leurs procédés d'utilisation
|
|
US8759490B2
(en)
|
2005-03-24 |
2014-06-24 |
Millennium Pharamaceuticals, Inc. |
Antibodies that bind OV064 and methods of use therefor
|
|
PT2343320T
(pt)
|
2005-03-25 |
2018-01-23 |
Gitr Inc |
Anticorpos anti-gitr e as suas utilizações
|
|
US20060240006A1
(en)
|
2005-04-20 |
2006-10-26 |
Chishih Chu |
Novel antibody structures derived from human germline sequences
|
|
EA200702361A1
(ru)
|
2005-04-27 |
2008-04-28 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
АНТИТЕЛА ПРОТИВ csPCNA ИЗОФОРМЫ И ИХ ПРИМЕНЕНИЕ
|
|
MX2007013978A
(es)
|
2005-05-09 |
2008-02-22 |
Ono Pharmaceutical Co |
Anticuerpos monoclonales humanos a muerte programada 1 (pd-1) y metodos para tratamiento de cancer utilizando anticuerpos anti-pd-1 solos o en combinacion con otros inmunoterapeuticos.
|
|
US7585960B2
(en)
|
2005-05-11 |
2009-09-08 |
Theramab Gmbh |
Nucleic acids encoding superagonistic anti-CD28 antibodies
|
|
WO2006125143A2
(fr)
|
2005-05-18 |
2006-11-23 |
Novartis Ag |
Methodes de diagnostic et de traitement des maladies proliferatives mediees par la signalisation cd40
|
|
EP2312315A1
(fr)
|
2005-05-18 |
2011-04-20 |
Novartis AG |
Procédés pour le diagnostic et le traitement des maladies ayant une composante auto-immune et/ou inflammatoire
|
|
KR100694508B1
(ko)
|
2005-05-24 |
2007-03-13 |
울산대학교 산학협력단 |
Ｈｂｂｋ４항체를 포함하는 암 질환 치료용 약학조성물및 이를 이용한 암의 면역치료 방법
|
|
ES2354865T3
(es)
|
2005-05-26 |
2011-03-18 |
Seattle Genetics, Inc. |
Anticuerpos anti-cd40 humanizados y métodos para utilizarlos.
|
|
CN105330741B
(zh)
|
2005-07-01 |
2023-01-31 |
E.R.施贵宝&圣斯有限责任公司 |
抗程序性死亡配体1(pd-l1)的人单克隆抗体
|
|
KR101395005B1
(ko)
|
2005-11-01 |
2014-05-21 |
조마 테크놀로지 리미티드 |
항ｃｄ40 항체의 용도
|
|
US8926979B2
(en)
|
2005-11-01 |
2015-01-06 |
Novartis Ag |
Treatment of cancer or pre-malignant conditions using anti-CD40 antibodies
|
|
JP2009514864A
(ja)
|
2005-11-07 |
2009-04-09 |
アボット・ラボラトリーズ |
Ｐ２ｘ７受容体拮抗薬および使用方法
|
|
TWI461436B
(zh)
|
2005-11-25 |
2014-11-21 |
Kyowa Hakko Kirin Co Ltd |
人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
|
|
BRPI0620601A2
(pt)
|
2005-12-08 |
2011-11-16 |
Medarex Inc |
anticorpo monoclonal humano isolado ou uma porção ligante ao antìgeno do mesmo, composição, imunoconjugado, molécula de ácido nucléico isolada, vetor de expressão, célula hospedeira, método para preparar um anticorpo anti-o8e e método para tratar ou prevenir uma doença definida pelo crescimento de células tumorais expressando o8e
|
|
CA2632698A1
(fr)
|
2005-12-09 |
2007-07-05 |
Seattle Genetics, Inc. |
Procedes d'utilisation d'agents de liaison de cd40
|
|
US20110008368A1
(en)
|
2006-01-13 |
2011-01-13 |
Board Of Regents, The University Of Texas System |
Methods of modulating the ox40 receptor to treat cancer
|
|
WO2007109201A2
(fr)
|
2006-03-16 |
2007-09-27 |
Renovis, Inc. |
Composés de bicyclohétéroaryle en tant que modulateur de p2x7 et leurs utilisations
|
|
BRPI0710826A2
(pt)
|
2006-04-21 |
2011-08-23 |
Novartis Ag |
composições farmacêuticas de anticorpo anti-cd40 antagonista
|
|
EP1854810A1
(fr)
|
2006-05-09 |
2007-11-14 |
PanGenetics B.V. |
Anticorps monoclonal anti CD40 humain déimmunisé et antagoniste dérivé de l'anticorps ch5D12
|
|
KR100745488B1
(ko)
|
2006-07-04 |
2007-08-02 |
학교법인 울산공업학원 |
항-4-1ｂｂ 항체 및 화학 항암제를 포함하는 암 질환 예방및 치료용 약학 조성물
|
|
WO2008043145A1
(fr)
|
2006-10-10 |
2008-04-17 |
Biosceptre International Limited |
Hybridomes produisant des anticorps dirigés contre le récepteur p2x7 non fonctionnel
|
|
GB0620894D0
(en)
|
2006-10-20 |
2006-11-29 |
Univ Southampton |
Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
|
|
CA2669921A1
(fr)
|
2006-11-15 |
2008-06-26 |
Medarex, Inc. |
Anticorps monoclonaux humains contre le btla et procedes d'utilisation
|
|
CN105037549B
(zh)
|
2007-01-11 |
2018-09-28 |
诺和诺德公司 |
抗-kir抗体、制剂及其应用
|
|
JP5357778B2
(ja)
|
2007-01-23 |
2013-12-04 |
ゼンコー・インコーポレイテッド |
最適化ｃｄ４０抗体および前記を使用する方法
|
|
KR20090122396A
(ko)
|
2007-03-22 |
2009-11-27 |
아스트라제네카 아베 |
염증성 질환 치료용 퀴놀린 유도체
|
|
KR20100014527A
(ko)
|
2007-03-22 |
2010-02-10 |
슬로안-케테링인스티튜트퍼캔서리서치 |
단일클론항체 8ｈ9의 용도
|
|
EA200970912A1
(ru)
|
2007-04-03 |
2010-02-26 |
Глэксо Груп Лимитед |
Карбоксамидные производные имидазолидина в качестве модуляторов p2x7
|
|
UA99610C2
(en)
|
2007-04-10 |
2012-09-10 |
Х. Луннбэк А/С |
Heteroaryl amide analogues as p2x7 antagonists
|
|
KR20100017514A
(ko)
|
2007-05-07 |
2010-02-16 |
메디뮨 엘엘씨 |
항 ｉｃｏｓ 항체, 및 종양, 이식 및 자가면역성 질환 치료에서의 이의 용도
|
|
EP2155685B1
(fr)
|
2007-05-10 |
2011-03-16 |
Glaxo Group Limited |
Dérivés du pyrazole utilisés comme modulateurs de p2x7
|
|
KR20080107050A
(ko)
|
2007-06-05 |
2008-12-10 |
울산대학교 산학협력단 |
항-ｃｄ１３７ 단일클론 항체를 포함하는 만성이식편대숙주 질환의 예방 또는 치료용 약학적 조성물
|
|
KR101562580B1
(ko)
|
2007-06-18 |
2015-10-22 |
머크 샤프 앤 도메 비.브이. |
사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
|
|
JPWO2009001673A1
(ja)
*
|
2007-06-26 |
2010-08-26 |
学校法人 城西大学 |
Ａｔｐ含有免疫アジュバント
|
|
WO2009014708A2
(fr)
|
2007-07-23 |
2009-01-29 |
Cell Genesys, Inc. |
Anticorps pd-1 en combinaison avec une cellule sécrétant de la cytokine et leurs procédés d'utilisation
|
|
FR2921342B1
(fr)
|
2007-09-20 |
2010-03-12 |
Airbus France |
Carenage aerodynamique arriere inferieur pour dispositif d'accrochage d'un moteur d'aeronef
|
|
US20100311749A1
(en)
|
2007-10-26 |
2010-12-09 |
Laura Jane Chambers |
4-benzoyl-1-substituted-piperazin-2-one derivatives as p2x7 modulators
|
|
JP5423679B2
(ja)
|
2007-10-31 |
2014-02-19 |
日産化学工業株式会社 |
ピリダジノン化合物及びｐ２ｘ７受容体阻害剤
|
|
EP2211902A1
(fr)
|
2007-11-09 |
2010-08-04 |
Novartis AG |
Utilisation d'anticorps anti-cd40
|
|
MX2010005830A
(es)
|
2007-11-30 |
2010-09-14 |
Bristol Myers Squibb Co |
Conjugado de anticuerpo monoclonal anti-b7h4 - farmaco y metodos de uso del mismo.
|
|
PE20091036A1
(es)
|
2007-11-30 |
2009-08-15 |
Astrazeneca Ab |
Derivado de quinolina como antagonista del receptor p2x7
|
|
CA2930393C
(fr)
|
2007-12-04 |
2022-11-29 |
Alnylam Pharmaceuticals, Inc. |
Conjugues glucidiques utilises en tant qu'agents d'administration pour des oligonucleotides
|
|
US8551485B2
(en)
|
2008-01-23 |
2013-10-08 |
Xencor, Inc. |
Anti-CD40 antibodies and methods of inhibiting proliferation of CD40 expressing cells
|
|
WO2009114335A2
(fr)
|
2008-03-12 |
2009-09-17 |
Merck & Co., Inc. |
Protéines de liaison avec pd-1
|
|
US8314068B2
(en)
|
2008-04-14 |
2012-11-20 |
University Hospitals Of Cleveland |
P2X7 inhibition of epithelial cancers and papillomas
|
|
US8431704B2
(en)
|
2008-04-22 |
2013-04-30 |
Janssen Pharmaceutica Nv |
Quinoline or isoquinoline substituted P2X7 antagonists
|
|
EP2279003A4
(fr)
|
2008-05-01 |
2013-04-03 |
Gtc Biotherapeutics Inc |
Anticorps anti-cd137 en tant qu'agent dans le traitement d'états inflammatoires
|
|
JP5425775B2
(ja)
|
2008-06-30 |
2014-02-26 |
協和発酵キリン株式会社 |
抗ｃｄ２７抗体
|
|
KR101548143B1
(ko)
|
2008-07-16 |
2015-08-28 |
베일러 리서치 인스티튜트 |
극대화된 Ｇａｇ 및 Ｎｅｆ를 수지상 세포에 표적화시킴을 기본으로 하는 ＨＩＶ 백신
|
|
US20110097339A1
(en)
|
2008-07-18 |
2011-04-28 |
Domantis Limited |
Compositions monovalent for CD28 binding and methods of use
|
|
JP2012507260A
(ja)
|
2008-07-18 |
2012-03-29 |
ドマンティス リミテッド |
Ｃｄ２８結合のための一価の組成物及び使用方法
|
|
CN105936648B
(zh)
|
2008-07-18 |
2020-06-16 |
百时美施贵宝公司 |
Cd28结合为单价的组合物及使用方法
|
|
US8927697B2
(en)
|
2008-09-12 |
2015-01-06 |
Isis Innovation Limited |
PD-1 specific antibodies and uses thereof
|
|
US9181342B2
(en)
|
2008-09-12 |
2015-11-10 |
Isis Innovation Limited |
PD-1 specific antibodies and uses thereof
|
|
CN102264762B
(zh)
|
2008-09-26 |
2018-03-27 |
达纳-法伯癌症研究公司 |
人抗pd‑1、pd‑l1和pd‑l2的抗体及其应用
|
|
WO2010042433A1
(fr)
|
2008-10-06 |
2010-04-15 |
Bristol-Myers Squibb Company |
Combinaison d'anticorps cd137 et d'anticorps ctla-4 pour le traitement de maladies prolifératives
|
|
WO2010065939A1
(fr)
|
2008-12-05 |
2010-06-10 |
Indiana University Research & Technology Corporation |
Traitement combiné pour améliorer la cytotoxicité induite par les cellules nk
|
|
BRPI0917592B1
(pt)
|
2008-12-09 |
2021-08-17 |
Genentech, Inc |
Anticorpo anti-pd-l1, composição, artigos manufaturados e usos de uma composição
|
|
EP2198873A1
(fr)
|
2008-12-18 |
2010-06-23 |
Aposcience AG |
Préparation pharmaceutique renfermant le surnageant de cultures de cellules mononucléaires sanguines
|
|
SG2014014708A
(en)
|
2009-02-17 |
2014-05-29 |
Ucb Pharma Sa |
Antibody molecules having specificity for human ox40
|
|
GB0903325D0
(en)
|
2009-02-26 |
2009-04-08 |
Univ Aberdeen |
Antibody molecules
|
|
CN106432493B
(zh)
|
2009-03-10 |
2020-01-31 |
贝勒研究院 |
抗-cd40抗体及其用途
|
|
CN105884903B
(zh)
|
2009-03-10 |
2019-12-06 |
贝勒研究院 |
靶向抗原呈递细胞的疫苗
|
|
GB0906274D0
(en)
|
2009-04-09 |
2009-05-20 |
Ge Healthcare Ltd |
Imaging the central nervous system
|
|
US8647623B2
(en)
|
2009-04-10 |
2014-02-11 |
Kyowa Hakko Kirin Co., Ltd |
Method for treatment of blood tumor using anti-TIM-3 antibody
|
|
JP5694921B2
(ja)
|
2009-04-20 |
2015-04-01 |
協和発酵キリン株式会社 |
アミノ酸変異が導入されたＩｇＧ２を有する抗体
|
|
JP5654001B2
(ja)
|
2009-04-29 |
2015-01-14 |
グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ |
Ｐ２Ｘ７調節因子としての５，６，７，８−テトラヒドロ［１，２，４］トリアゾロ［４，３−ａ］ピラジン誘導体
|
|
GB0907515D0
(en)
|
2009-04-30 |
2009-06-10 |
Glaxo Group Ltd |
Compounds
|
|
WO2010132389A2
(fr)
|
2009-05-14 |
2010-11-18 |
University Of Maryland, Baltimore |
Procédés de traitement de cancers et de maladies associées à l'expression de 4-1bb (cd137)
|
|
ES2352780B2
(es)
*
|
2009-06-04 |
2011-09-15 |
Laboratorios Ovejero S.A. |
Lipopolisacárido de ochrobactrum intermedium contra la sepsis.
|
|
CA2768396A1
(fr)
|
2009-07-30 |
2011-02-03 |
F. Hoffmann-La Roche Ag |
Amides de dihydropyrimidone utilises comme modulateurs p2x7
|
|
CN102762593B
(zh)
|
2009-07-31 |
2015-05-20 |
梅达雷克斯有限责任公司 |
抗btla的完全人抗体
|
|
RU2595409C2
(ru)
|
2009-09-03 |
2016-08-27 |
Мерк Шарп И Доум Корп., |
Анти-gitr-антитела
|
|
WO2011031063A2
(fr)
|
2009-09-09 |
2011-03-17 |
울산대학교 산학협력단 |
Composition de prévention ou de traitement de troubles métaboliques contenant l'anticorps anti-4-1bb
|
|
US8871760B2
(en)
|
2009-09-21 |
2014-10-28 |
Roche Palo Alto Llc |
[1,2,4]triazolo[3,4-C][1,4]oxazines as P2X7 modulators
|
|
GB0919594D0
(en)
|
2009-11-09 |
2009-12-23 |
Glaxo Group Ltd |
Compounds
|
|
RS60033B1
(sr)
|
2009-11-24 |
2020-04-30 |
Medimmune Ltd |
Ciljano vezujući agensi usmereni na b7-h1
|
|
KR101853702B1
(ko)
|
2009-12-07 |
2018-05-03 |
더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 |
항-종양 항체 치료를 향상시키는 방법
|
|
KR101773216B1
(ko)
|
2009-12-29 |
2017-08-31 |
교와 핫꼬 기린 가부시키가이샤 |
항 ｃｄ27 항체
|
|
KR20110085038A
(ko)
|
2010-01-19 |
2011-07-27 |
울산대학교 산학협력단 |
항 ｃｄ137-항체 및 독소 결합물을 이용한 ｃｄ137 양성세포의 제거방법
|
|
WO2011091078A2
(fr)
|
2010-01-19 |
2011-07-28 |
Xencor, Inc. |
Variants d'anticorps possédant une activité complémentaire accrue
|
|
JP5992340B2
(ja)
|
2010-02-18 |
2016-09-14 |
エフィミュヌＥｆｆｉｍｕｎｅ |
抗ｃｄ２８ヒト化抗体
|
|
LT2542256T
(lt)
|
2010-03-04 |
2019-10-25 |
Macrogenics Inc |
Su b7-h3 reaguojantys antikūnai, jų imunologiškai aktyvūs fragmentai ir jų naudojimas
|
|
PH12012501751A1
(en)
|
2010-03-04 |
2012-11-12 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
RS57114B1
(sr)
|
2010-03-31 |
2018-06-29 |
Boehringer Ingelheim Int |
Anti-cd40 antitela
|
|
WO2011127324A2
(fr)
|
2010-04-08 |
2011-10-13 |
JN Biosciences, LLC |
Anticorps anti-cd122
|
|
US20120213771A1
(en)
|
2010-04-13 |
2012-08-23 |
Celldex Therapeutics Inc. |
Antibodies that bind human cd27 and uses thereof
|
|
KR101958753B1
(ko)
|
2010-04-13 |
2019-03-15 |
셀덱스 쎄라퓨틱스, 인크. |
인간 ｃｄ27에 결합하는 항체 및 이의 용도
|
|
JP5513242B2
(ja)
|
2010-04-28 |
2014-06-04 |
オリンパス株式会社 |
撮像装置
|
|
AU2011262758B8
(en)
|
2010-06-11 |
2014-09-04 |
Kyowa Kirin Co., Ltd. |
Anti-tim-3 antibody
|
|
JP6023706B2
(ja)
|
2010-07-09 |
2016-11-09 |
アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップＡｄｕｒｏ Ｂｉｏｔｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｅｕｒｏｐｅ Ｂ．Ｖ． |
Ｃｄ２７に対するアゴニスト抗体
|
|
WO2013028231A1
(fr)
|
2011-08-23 |
2013-02-28 |
Board Of Regents, The University Of Texas System |
Anticorps anti-ox40 et leurs procédés d'utilisation
|
|
AP2013006771A0
(en)
|
2010-08-23 |
2013-03-31 |
Boards Of Regents The University Of Texas System |
Anti-OX40 antibodies and methods of using the same
|
|
SI2614082T1
(sl)
|
2010-09-09 |
2018-12-31 |
Pfizer Inc. |
Molekule, ki vežejo 4-1BB
|
|
CA2812046A1
(fr)
|
2010-09-15 |
2012-03-22 |
Alnylam Pharmaceuticals, Inc. |
Agents a base d'arni modifies
|
|
JP2013249256A
(ja)
|
2010-09-15 |
2013-12-12 |
Astellas Pharma Inc |
脂肪性肝疾患治療薬
|
|
AR083847A1
(es)
|
2010-11-15 |
2013-03-27 |
Novartis Ag |
Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
|
|
JP6224457B2
(ja)
|
2010-11-22 |
2017-11-01 |
イネイト・ファルマ・ソシエテ・アノニム |
Ｎｋ細胞調節治療及び悪性血液疾患の治療方法
|
|
WO2012075111A1
(fr)
|
2010-11-30 |
2012-06-07 |
Novartis Ag |
Utilisation d'anticorps anti-cd40 en thérapie combinée contre des cancers associés aux cellules b
|
|
US20120149718A1
(en)
|
2010-12-14 |
2012-06-14 |
Brotherton-Pleiss Christine E |
Amido Compounds
|
|
US20120157494A1
(en)
|
2010-12-16 |
2012-06-21 |
Harris Iii Ralph New |
Isoindolyl compounds
|
|
AU2011349502B2
(en)
|
2010-12-20 |
2016-12-22 |
The Rockefeller University |
Modulating agonistic TNFR antibodies
|
|
WO2012109238A2
(fr)
|
2011-02-07 |
2012-08-16 |
President And Fellows Of Harvard College |
Procédés d'augmentation des réponses immunitaires à l'aide d'agents qui se lient directement à ire-1 et activent ire-1
|
|
EP2676677B1
(fr)
|
2011-02-17 |
2019-05-22 |
Kyowa Hakko Kirin Co., Ltd. |
Préparation pharmaceutique d'anticorps anti-cd40 très concentrée
|
|
US20140073651A1
(en)
|
2011-02-22 |
2014-03-13 |
Actelion Pharmaceuticals Ltd. |
Benzamide derivatives as p2x7 receptor antagonists
|
|
GB201103955D0
(en)
|
2011-03-09 |
2011-04-20 |
Antitope Ltd |
Antibodies
|
|
CN106279401A
(zh)
|
2011-03-11 |
2017-01-04 |
贝丝以色列女执事医疗中心 |
Cd40片段及其用途
|
|
SG193428A1
(en)
|
2011-03-31 |
2013-10-30 |
Inst Nat Sante Rech Med |
Antibodies directed against icos and uses thereof
|
|
CA3019531A1
(fr)
|
2011-04-19 |
2012-10-26 |
Pfizer Inc. |
Combinaisons d'anticorps anti-4-1bb et d'anticorps induisant une cytotoxicite a mediation cellulaire dependante d'un anticorps (adcc) pour le traitement du cancer
|
|
WO2012145493A1
(fr)
|
2011-04-20 |
2012-10-26 |
Amplimmune, Inc. |
Anticorps et autres molécules qui se lient à b7-h1 et à pd-1
|
|
JP6114256B2
(ja)
|
2011-04-21 |
2017-04-12 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
Ｃｄ４０を拮抗する抗体ポリペプチド
|
|
SG194620A1
(en)
|
2011-04-25 |
2013-12-30 |
Daiichi Sankyo Co Ltd |
Anti-b7-h3 antibody
|
|
WO2012149285A1
(fr)
|
2011-04-28 |
2012-11-01 |
Claire Mitchell |
Méthode de traitement d'une dégénérescence maculaire par la modulation des récepteurs p2y12 ou p2x7
|
|
JP6125489B2
(ja)
|
2011-04-29 |
2017-05-10 |
アペクシジェン， インコーポレイテッド |
抗ｃｄ４０抗体および使用方法
|
|
CA2837184C
(fr)
|
2011-05-25 |
2021-09-21 |
Innate Pharma, S.A. |
Anticorps anti-kir destines au traitement de troubles inflammatoires
|
|
EP2726095B1
(fr)
|
2011-07-01 |
2018-06-06 |
Biosceptre (Aust) Pty Ltd |
Polythérapie
|
|
WO2013006490A2
(fr)
|
2011-07-01 |
2013-01-10 |
Cellerant Therapeutics, Inc. |
Anticorps se liant spécifiquement à tim3
|
|
CA3158257A1
(fr)
|
2011-07-11 |
2013-01-17 |
Ichnos Sciences SA |
Anticorps qui se lient a l'ox40 et leurs utilisations
|
|
CA2838640C
(fr)
|
2011-07-22 |
2019-06-11 |
Actelion Pharmaceuticals Ltd |
Derives d'amides heterocycliques utilises comme antagonistes du recepteur p2x7
|
|
AU2012296613B2
(en)
|
2011-08-15 |
2016-05-12 |
Amplimmune, Inc. |
Anti-B7-H4 antibodies and their uses
|
|
GB201115280D0
(en)
|
2011-09-05 |
2011-10-19 |
Alligator Bioscience Ab |
Antibodies, uses and methods
|
|
US20130108641A1
(en)
|
2011-09-14 |
2013-05-02 |
Sanofi |
Anti-gitr antibodies
|
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
|
WO2013067492A1
(fr)
|
2011-11-03 |
2013-05-10 |
The Trustees Of The University Of Pennsylvania |
Compositions spécifiques de b7-h4 isolé et procédés d'utilisation associés
|
|
UA112203C2
(uk)
|
2011-11-11 |
2016-08-10 |
Юсб Фарма С.А. |
Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
|
|
EP2604265A1
(fr)
|
2011-12-17 |
2013-06-19 |
Royal College of Surgeons in Ireland (RCSI) |
Antagonistes P2x7 en tant que traitement auxiliaire ou principal contre l'état de mal épileptique
|
|
HK1206251A1
(en)
|
2012-03-15 |
2016-01-08 |
Janssen Biotech, Inc. |
Human anti-cd27 antibodies, methods and uses
|
|
US20140004131A1
(en)
|
2012-05-04 |
2014-01-02 |
Novartis Ag |
Antibody formulation
|
|
JP2015519375A
(ja)
|
2012-05-31 |
2015-07-09 |
ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． |
Ｐｄ−ｌ１に結合する抗原結合蛋白質
|
|
KR101549637B1
(ko)
|
2012-06-08 |
2015-09-03 |
국립암센터 |
신규한 Ｔｈ1 세포 전환용 에피토프 및 이의 용도
|
|
SG10201610251PA
(en)
|
2012-06-08 |
2017-01-27 |
Aduro Biotech |
Compositions and methods for cancer immunotherapy
|
|
US9268936B2
(en)
|
2012-07-27 |
2016-02-23 |
Mandiant, Llc |
Physical memory forensics system and method
|
|
US9845356B2
(en)
|
2012-08-03 |
2017-12-19 |
Dana-Farber Cancer Institute, Inc. |
Single agent anti-PD-L1 and PD-L2 dual binding antibodies and methods of use
|
|
ES2684552T3
(es)
|
2012-09-03 |
2018-10-03 |
Inserm - Institut National De La Santé Et De La Recherche Médicale |
Anticuerpos dirigidos contra ICOS para tratar la enfermedad de injerto contra hospedador
|
|
PT2904011T
(pt)
|
2012-10-02 |
2017-10-27 |
Bristol Myers Squibb Co |
Combinação de anticorpos anti-kir e anticorpos anti-pd-1 para tratar cancro
|
|
US10195288B2
(en)
|
2012-10-11 |
2019-02-05 |
Daiichi Sankyo Company, Limited |
Antibody-drug conjugate
|
|
TW201427947A
(zh)
|
2012-10-12 |
2014-07-16 |
Lundbeck & Co As H |
環狀胺
|
|
TWI598325B
(zh)
|
2012-10-12 |
2017-09-11 |
Ｈ 朗德貝克公司 |
苯甲醯胺類
|
|
WO2014061277A1
(fr)
|
2012-10-19 |
2014-04-24 |
第一三共株式会社 |
Conjugué anticorps-médicament produit par liaison par l'intermédiaire d'un lieur ayant une structure hydrophile
|
|
WO2014066532A1
(fr)
|
2012-10-23 |
2014-05-01 |
Bristol-Myers Squibb Company |
Association d'anticorps anti-kir et anti-ctla-4 pour le traitement du cancer
|
|
JP2016011258A
(ja)
|
2012-10-26 |
2016-01-21 |
株式会社ペルセウスプロテオミクス |
抗ヒトｃｄ４０モノクローナル抗体及びその利用
|
|
WO2014065402A1
(fr)
|
2012-10-26 |
2014-05-01 |
株式会社ペルセウスプロテオミクス |
Anticorps monoclonal anti-cd-40 humain, et utilisation correspondante
|
|
DK2914627T3
(da)
|
2012-10-30 |
2021-07-12 |
Apexigen Inc |
Anti-cd40-antistoffer og fremgangsmåder til anvendelse
|
|
WO2014074529A1
(fr)
*
|
2012-11-06 |
2014-05-15 |
The Board Of Regents Of The University Of Texas System |
Méthodes de traitement d'un cancer primaire et de la métastase cancéreuse
|
|
PT2931738T
(pt)
|
2012-12-13 |
2019-04-10 |
Aduro Biotech Inc |
Composições compreendendo nucleótidos cíclicos de purina com estereoquímica definida e métodos para a sua preparação e utilização
|
|
KR102232744B1
(ko)
|
2012-12-18 |
2021-03-26 |
이도르시아 파마슈티컬스 리미티드 |
Ｐ２ｘ７ 수용체 길항제로서의 인돌 카르복사미드 유도체
|
|
JP2016509582A
(ja)
|
2012-12-19 |
2016-03-31 |
アンプリミューン， インコーポレイテッド |
抗ヒトｂ７−ｈ４抗体およびその使用
|
|
WO2014099824A1
(fr)
*
|
2012-12-19 |
2014-06-26 |
Board Of Regents, The University Of Texas System |
Ciblage pharmaceutique d'une voie de signalisation de dinucléotide cyclique chez un mammifère
|
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
|
US9388197B2
(en)
|
2013-01-22 |
2016-07-12 |
Actelion Pharmaceuticals Ltd. |
Heterocyclic amide derivatives as P2X7 receptor antagonists
|
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
CN105189552B
(zh)
|
2013-03-14 |
2019-08-02 |
基因泰克公司 |
抗b7-h4抗体和免疫缀合物
|
|
JP6467404B2
(ja)
|
2013-03-14 |
2019-02-13 |
ヤンセン ファーマシューティカ エヌ．ベー． |
Ｐ２ｘ７モジュレーター
|
|
JO3509B1
(ar)
|
2013-03-14 |
2020-07-05 |
Janssen Pharmaceutica Nv |
معدلات p2x7
|
|
JP6294953B2
(ja)
|
2013-03-14 |
2018-03-14 |
ヤンセン ファーマシューティカ エヌ．ベー． |
Ｐ２ｘ７調節物質
|
|
TWI599567B
(zh)
|
2013-03-14 |
2017-09-21 |
健生藥品公司 |
Ｐ２ｘ７調節劑
|
|
US20140322236A1
(en)
|
2013-03-15 |
2014-10-30 |
Sdix, Llc |
Anti-human adora2a antibodies
|
|
WO2014140374A2
(fr)
|
2013-03-15 |
2014-09-18 |
Novo Nordisk A/S |
Anticorps monovalents anti-cd27
|
|
DK2976361T3
(en)
|
2013-03-18 |
2018-10-01 |
Biocerox Prod Bv |
HUMANIZED ANTI-CD134- (0X40) ANTIBODIES AND APPLICATIONS THEREOF
|
|
WO2014165422A1
(fr)
|
2013-04-02 |
2014-10-09 |
Merck Sharp & Dohme Corp. |
Test immunohistochimique pour détecter l'expression du ligand de mort programmée 1 (pd-l1) dans un tissu tumoral
|
|
PT2996473T
(pt)
|
2013-05-18 |
2019-11-18 |
Univ California |
Composições e métodos para a ativação da sinalização dependente do ''estimulador de genes de interferão''
|
|
AU2014268298B2
(en)
|
2013-05-24 |
2019-01-17 |
Medlmmune, Llc |
Anti-B7-H5 antibodies and their uses
|
|
US9676853B2
(en)
|
2013-05-31 |
2017-06-13 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind PD-1
|
|
JP6824735B2
(ja)
|
2013-06-06 |
2021-02-03 |
ピエール、ファーブル、メディカマン |
抗Ｃ１０ｏｒｆ５４抗体およびその使用方法
|
|
WO2014209168A1
(fr)
|
2013-06-24 |
2014-12-31 |
Kim Ruslan Zynsonovich |
Communicateur automobile
|
|
GB201311487D0
(en)
|
2013-06-27 |
2013-08-14 |
Alligator Bioscience Ab |
Bispecific molecules
|
|
CA2917858A1
(fr)
|
2013-08-02 |
2015-02-05 |
Aduro Biotech Holdings, Europe B.V. |
Combinaison d'agonistes cd27 et d'inhibiteurs de points de controle immunitaires pour une stimulation immune
|
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
|
WO2015036394A1
(fr)
|
2013-09-10 |
2015-03-19 |
Medimmune Limited |
Anticorps contre pd-1 et leurs utilisations
|
|
US9642830B2
(en)
*
|
2013-10-21 |
2017-05-09 |
Drexel University |
Use of sting agonists to treat hepatitis B virus infection
|
|
US10494433B2
(en)
|
2013-11-06 |
2019-12-03 |
Bristol-Myers Squibb Company |
Combination of anti-KIR and anti-CS1 antibodies to treat multiple myeloma
|
|
GB201322583D0
(en)
|
2013-12-19 |
2014-02-05 |
Alligator Bioscience Ab |
Antibodies
|
|
MX2016008099A
(es)
|
2013-12-20 |
2016-10-13 |
Hoffmann La Roche |
Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40.
|
|
EP3102604B1
(fr)
|
2014-02-04 |
2020-01-15 |
Pfizer Inc |
Combinaison d'un antagoniste de pd -1 et d'un agoniste de 4-1bb pour le traitement du cancer
|
|
EP2905282A1
(fr)
|
2014-02-05 |
2015-08-12 |
AXXAM S.p.A. |
Thiazole ou oxazole substituée en tant qu'antagonistes du récepteur P2X7
|
|
WO2015134988A1
(fr)
|
2014-03-07 |
2015-09-11 |
Bristol-Myers Squibb Company |
Procédé d'utilisation de polypeptides d'anticorps qui sont des antagonistes de cd40 pour traiter une affection intestinale inflammatoire (aii)
|
|
US10023649B2
(en)
|
2014-05-21 |
2018-07-17 |
Pfizer Inc. |
Method of treating cancer with a combination of an anti-CCR4 antibody and a 4-1BB agonist
|
|
MX377844B
(es)
|
2014-05-28 |
2025-03-11 |
Agenus Inc |
Anticuerpos anti proteína relacionada con el receptor del factor de necrosis tumoral inducida por glucocorticóides (gitr) y sus métodos de uso.
|
|
AU2015265976B2
(en)
|
2014-05-29 |
2019-08-01 |
Ventana Medical Systems, Inc. |
Anti-B7-H3 antibodies and diagnostic uses thereof
|
|
PT3151921T
(pt)
|
2014-06-06 |
2019-11-21 |
Bristol Myers Squibb Co |
Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos
|
|
WO2015188047A1
(fr)
|
2014-06-06 |
2015-12-10 |
University Of Maryland, Baltimore |
Anticorps monoclonaux anti-cd-137 présentant des capacités de liaison distinctes au fcγr pour le traitement d'un cancer ou d'une auto-immunité
|
|
EP3157563A1
(fr)
|
2014-06-23 |
2017-04-26 |
TheraMAB LLC |
Compositions et méthodes pour une immunothérapie efficace et sûre
|
|
EP3166665A1
(fr)
|
2014-07-09 |
2017-05-17 |
Novo Nordisk A/S |
Dispositif d'administration de médicament motorisé
|
|
CN105296433B
(zh)
|
2014-08-01 |
2018-02-09 |
中山康方生物医药有限公司 |
一种ctla4抗体、其药物组合物及其用途
|
|
PE20170680A1
(es)
|
2014-08-12 |
2017-06-14 |
Alligator Bioscience Ab |
Tratamientos conjuntos con anticuerpos anti cd40
|
|
WO2016023875A1
(fr)
|
2014-08-14 |
2016-02-18 |
F. Hoffmann-La Roche Ag |
Polythérapie d'anticorps activant le cd-40 humain et d'anticorps anti-pd-l1 humain
|
|
US20170233485A1
(en)
|
2014-08-18 |
2017-08-17 |
Biogen Ma Inc. |
Anti-cd40 antibodies and uses thereof
|
|
EP3183269A2
(fr)
|
2014-08-22 |
2017-06-28 |
Bristol-Myers Squibb Company |
Traitement du cancer à l'aide d'une combinaison d'un anticorps anti-pd-1 et d'un anticorps anti-cd137
|
|
EP3186277B1
(fr)
|
2014-08-27 |
2020-10-07 |
Memorial Sloan Kettering Cancer Center |
Anticorps, compositions et leurs utilisations
|
|
SI3186283T1
(sl)
|
2014-08-29 |
2020-04-30 |
F. Hoffmann-La Roche Ag |
Kombinirana terapija z imunocitokini različice IL-2, usmerjenimi proti tumorju in protitelesi proti humanemu PD-L1
|
|
CN113698485A
(zh)
|
2014-09-12 |
2021-11-26 |
基因泰克公司 |
抗-b7-h4抗体及免疫缀合物
|
|
MX2017004311A
(es)
|
2014-10-03 |
2017-12-07 |
Dana Farber Cancer Inst Inc |
Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos.
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
KR20170075778A
(ko)
|
2014-10-27 |
2017-07-03 |
에이전시 포 사이언스, 테크놀로지 앤드 리서치 |
항-tim-3 항체
|
|
GB201419094D0
(en)
|
2014-10-27 |
2014-12-10 |
Agency Science Tech & Res |
Anti-TIM-3-antibodies
|
|
EP3212227B1
(fr)
|
2014-10-28 |
2020-01-15 |
Children's University Hospital Tübingen |
Traitement avec un anticorps anti-kir de patients pédiatriques atteints de leucémie lymphoblastique à précurseurs b (bcp-all)
|
|
CN107073118B
(zh)
|
2014-10-29 |
2022-03-01 |
西雅图基因公司 |
非岩藻糖基化抗cd40抗体的剂量和给药
|
|
EP3223865A4
(fr)
|
2014-10-31 |
2018-10-03 |
Jounce Therapeutics, Inc. |
Méthodes de traitement d'états pathologiques avec des anticorps qui se lient à b7-h4
|
|
PL3215532T3
(pl)
|
2014-11-06 |
2020-03-31 |
F. Hoffmann-La Roche Ag |
Przeciwciała anty-TIM3 i sposoby ich zastosowania
|
|
SI3333191T1
(sl)
|
2014-12-11 |
2021-03-31 |
Pierre Fabre Medicament |
Proti C10ORF54 protitelesa in uporaba le-teh
|
|
EP3546473B1
(fr)
|
2014-12-16 |
2025-12-10 |
Kayla Therapeutics |
Dinucléotides cycliques [(2',5')p(3',5')p] fluorés pour l'induction de la cytokine
|
|
WO2016096577A1
(fr)
|
2014-12-16 |
2016-06-23 |
Invivogen |
Utilisation combinée d'un agent chimiothérapeutique et d'un dinucléotide cyclique pour le traitement du cancer
|
|
WO2016106004A1
(fr)
|
2014-12-23 |
2016-06-30 |
Full Spectrum Genetics, Inc. |
Nouveaux composés de liaison anti-b7h3 et leurs utilisations
|
|
US20160200815A1
(en)
|
2015-01-05 |
2016-07-14 |
Jounce Therapeutics, Inc. |
Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
|
|
HK1248603A1
(zh)
|
2015-03-10 |
2018-10-19 |
Aduro Biotech, Inc. |
用於活化"干扰素基因的刺激剂"依懒性信号传导的组合物和方法
|
|
EP3685830A1
(fr)
*
|
2015-05-20 |
2020-07-29 |
Institut National De La Sante Et De La Recherche Medicale - Inserm |
Procédés et composition pharmaceutique pour moduler la polarisation et l'activation de macrophages
|
|
SG10202010609QA
(en)
|
2015-08-13 |
2020-11-27 |
Merck Sharp & Dohme |
Cyclic di-nucleotide compounds as sting agonists
|
|
EP3368072A4
(fr)
|
2015-10-28 |
2019-07-03 |
Aduro BioTech, Inc. |
Compositions et procédés d'activation de la signalisation dépendante de « stimulateur de gènes d'interféron »
|
|
DE212016000029U1
(de)
|
2015-12-07 |
2017-07-30 |
Opi Vi - Ip Holdco Llc |
Zusammensetzungen von Antikörperkonstrukt-Agonist-Konjugaten
|
|
US10723756B2
(en)
|
2016-01-11 |
2020-07-28 |
Innate Tumor Immunity Inc. |
Cyclic dinucleotides for treating conditions associated with STING activity such as cancer
|
|
WO2017180769A1
(fr)
|
2016-04-13 |
2017-10-19 |
Capten Therapeutics Inc. |
Petites molécules pour le traitement immunogène du cancer
|
|
EP3507367A4
(fr)
|
2016-07-05 |
2020-03-25 |
Aduro BioTech, Inc. |
Composés dinucléotidiques cycliques d'acide nucléique bloqué et leurs utilisations
|
|
WO2018045204A1
(fr)
|
2016-08-31 |
2018-03-08 |
Ifm Therapeutics, Inc |
Analogues de dinucléotides cycliques pour traiter des états associés à l'activité de la piqûre (stimulateur des gènes de l'interféron)
|
|
MA46452B1
(fr)
|
2016-10-04 |
2021-10-29 |
Merck Sharp & Dohme |
Composés de benzo[b]thiophéne en tant qu'agonistes de sting
|
|
JOP20170188A1
(ar)
|
2016-11-25 |
2019-01-30 |
Janssen Biotech Inc |
ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting)
|
|
JOP20170192A1
(ar)
|
2016-12-01 |
2019-01-30 |
Takeda Pharmaceuticals Co |
داي نوكليوتيد حلقي
|
|
RU2019122598A
(ru)
|
2016-12-20 |
2021-01-22 |
Мерк Шарп И Доум Корп. |
Циклические динуклеотидные агонисты sting для лечения рака
|
|
RU2019122602A
(ru)
|
2016-12-20 |
2021-01-22 |
Мерк Шарп И Доум Корп. |
Комбинации антагонистов pd-1 и циклических динуклеотидных агонистов sting для лечения рака
|
|
JP7275031B2
(ja)
|
2017-01-27 |
2023-05-17 |
ヤンセン バイオテツク，インコーポレーテツド |
Ｓｔｉｎｇアゴニストとしての環状ジヌクレオチド
|
|
CN110234404A
(zh)
|
2017-01-27 |
2019-09-13 |
詹森生物科技公司 |
作为sting激动剂的环状二核苷酸
|
|
JOP20190218A1
(ar)
|
2017-03-22 |
2019-09-22 |
Boehringer Ingelheim Int |
مركبات ثنائية النيوكليوتيدات حلقية معدلة
|
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
|
AR113224A1
(es)
|
2017-04-28 |
2020-02-19 |
Novartis Ag |
Conjugados de anticuerpo que comprenden un agonista de sting
|
|
EP3621624B1
(fr)
|
2017-05-12 |
2023-08-30 |
Merck Sharp & Dohme LLC |
Composés dinucléotidiques cycliques en tant qu'agonistes sting
|
|
US20200138827A1
(en)
|
2017-06-22 |
2020-05-07 |
Curadev Pharma Limited |
Small molecule modulators of human sting
|
|
JP2020524718A
(ja)
|
2017-06-22 |
2020-08-20 |
キュラデブ・ファーマ・リミテッドＣｕｒａｄｅｖ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ |
ヒトｓｔｉｎｇの複素環式小分子調節因子
|
|
PE20200696A1
(es)
|
2017-06-22 |
2020-06-16 |
Curadev Pharma Ltd |
Moduladores de moleculas pequenas de sting humana
|
|
CA3071538A1
(fr)
|
2017-08-04 |
2019-02-07 |
Merck Sharp & Dohme Corp. |
Agonistes benzo[b]thiophene de sting pour le traitement du cancer
|
|
AU2018311965A1
(en)
|
2017-08-04 |
2020-02-13 |
Merck Sharp & Dohme Llc |
Combinations of PD-1 antagonists and benzo[b]thiophene sting antagonists for cancer treatment
|
|
CN107335049B
(zh)
*
|
2017-08-18 |
2019-10-18 |
中国药科大学 |
菊科类型环肽化合物作为cGAS-STING信号通路抑制剂的应用
|
|
EP3675859A4
(fr)
|
2017-08-31 |
2021-06-30 |
Sperovie Biosciences, Inc. |
Composés, compositions et méthodes pour le traitement d'une maladie
|
|
US11707531B2
(en)
|
2017-09-11 |
2023-07-25 |
F-star Therapeutics, Inc. |
Compounds, compositions, and methods for the treatment of disease
|
|
CN111212839A
(zh)
|
2017-09-15 |
2020-05-29 |
艾杜罗生物科技公司 |
吡唑并嘧啶酮化合物及其用途
|
|
JP7262451B2
(ja)
|
2017-10-05 |
2023-04-21 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
Ｓｔｉｎｇアゴニストの投与方法
|
|
EP3692033A1
(fr)
|
2017-10-05 |
2020-08-12 |
GlaxoSmithKline Intellectual Property Development Limited |
Modulateurs de stimulateur des gènes (sting) d'interféron utiles dans le traitement du vih
|